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Abstract
Research associating the increased prevalence of familial autoimmunity with neuropsychiat-
ric disorders is reliant upon the ascertainment of history of autoimmune diseases from rela-
tives. To characterize the accuracy of self-report, we compared self-reported diagnoses of
18 autoimmune diseases using an online self-report questionnaire to the electronic medical
record (EMR) diagnoses in 1,013 adult (age 18–70 years) patients of a primary care clinic.
For the 11 diseases meeting our threshold observed prevalence, we estimated sensitivity,
specificity, positive predictive value (PPV), and negative predictive value (NPV) for self-
reported diagnoses under the assumption that EMR-based diagnoses were accurate. Six
diseases out of 11 had either sensitivity or PPV below 50%, with the lowest PPV for derma-
tological and endocrinological diseases. Common errors included incorrectly self-reporting
type 2 diabetes mellitus (DM), when type 1 DM was indicated by the EMR, and reporting
rheumatoid arthritis when osteoarthritis was indicated by the EMR. Results suggest that
ascertainment of familial autoimmunity through self-report contributes to inconsistencies
and inaccuracies in studies of autoimmune disease history and that future studies would
benefit from incorporating EMR review and biological measures.
Introduction
Immune dysfunction contributes to the pathophysiology of a number of neuropsychiatric dis-
orders.[1] At the clinical descriptive level, studies have found a higher prevalence of familial
autoimmunity in individuals with different neuropsychiatric disorders, including autism spec-
trum disorder (ASD),[2, 3] attention-deficit/hyperactivity disorder (ADHD),[4] obsessive-
compulsive disorder (OCD),[5] Tourette’s disorder,[5] and schizophrenia,[6] among others.
Understanding of association between familial autoimmunity and neuropsychiatric disorders
can help in identifying subtypes of these disorders and guide treatment discovery.[7]
A limitation of interpreting studies that evaluate the association between family history of
autoimmune disease and the risk of neuropsychiatric disorders in offspring is that the results
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may vary widely depending on the study design. For instance, the design of family studies pub-
lished to date can be categorized as either registry-based[8–10] or questionnaire-based.[11–15]
Both of these approaches have strengths and weaknesses. In registry-based studies, the family
history of autoimmune disease is extracted from medical-record-based registries. Registry-
based studies often have the advantage of large sample sizes. However, since autoimmune dis-
eases are rare, identifying a sample of adequate size can be challenging even in large population
studies, especially when the exposure or outcome being associated with autoimmune disease is
also rare (i.e. particular neuropsychiatric disorders). In addition, diagnostic accuracy is often
uncertain. Probands and family members are not readily available to query should clarification
or additional information be needed about diagnoses in the registry. In many cases the pres-
ence or absence of standardized diagnostic codes in the records are used to determine diagnos-
tic history,[8–10, 16, 17] a practice that can result in false positives. The presence of these
codes does not necessarily establish a reliable history of the disorder or disease for the patient;
codes may have been entered for reasons other than establishing the patient’s diagnosis, such
as explaining the initial reason for a visit or obtaining insurance reimbursement. Furthermore,
some patients may have been diagnosed based on clinical impression without verification by
laboratory testing or consultation from a specialist. In addition to false positives, false negatives
can result from patients receiving medical care outside of the system covered by the registry.
In questionnaire-based family studies, family history of autoimmune diseases is collected
via questionnaires asking participants to self-report whether they and sometimes their relatives
have been diagnosed with an autoimmune disease.[11–15] This design allows researchers to
conduct a detailed examination of probands with neuropsychiatric disorders in order to estab-
lish valid clinical diagnoses and to further characterize phenotype. Although this study design
gives investigators direct access to the patients and their relatives, the accuracy of self-reported
autoimmune disease diagnoses has not typically been verified either by medical record review
or by clinical assessment. In addition, using a questionnaire-based approach can introduce
bias in risk estimates due to differential self-reporting of suspected risk factors among families
of probands diagnosed with neuropsychiatric disorders.
The convenience and the potential pitfalls of the questionnaire-based design warrant inves-
tigation into the accuracy of self-report diagnosis. However, there are over 80 known autoim-
mune diseases affecting humans that vary widely in age of onset, prevalence, and severity.[18]
Because of the low prevalence of the majority of autoimmune diseases, previous studies inves-
tigated the accuracy of self-reports for the few more common diseases. Several studies have
evaluated the validity of self-reported diagnosis of certain autoimmune diseases, including
hypothyroidism,[19, 20] diabetes mellitus (DM; including both type 1 and type 2),[21] rheu-
matoid arthritis (RA),[22–26] and psoriasis[27]. These studies typically determined accuracy
of self-reports by reviewing the medical records of patients who reported a diagnosis. A limita-
tion of this approach is that it cannot determine the number of individuals who have a diagno-
sis of autoimmune disease but do not report it (i.e. false negatives). In addition, these studies
were often focused on the presence of one autoimmune disease, making it difficult to compare
the accuracy of self-report across autoimmune diseases.
As part of a pilot study assessing the feasibility of using a self-report questionnaire to inves-
tigate history of autoimmune disease, we compared self-reported history of autoimmune dis-
ease in conjunction with electronic medical record (EMR) review for the 18 most common
autoimmune diseases. This study was an initial step toward the longer-term goal of investigat-
ing the phenotypic correlates of family history of autoimmune disease in ASD. Medical record
review is a commonly accepted way to validate self-reports,[19] but it is subject to challenges
in physically obtaining a copy of medical records.[25, 28–30] To best overcome this challenge,
we conducted this study at a large hospital-based adult primary care practice, which allowed
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for full access to EMR. With Institutional Review Board (IRB) approval and informed consent
of individuals, we characterized the accuracy of self-report for the most prevalent autoimmune
diseases using EMR-based diagnosis as the ‘gold standard’. Because this was a pilot study, we
did not power it to demonstrate that the sensitivity and positive predictive value (PPV) of the
questionnaire were above a given minimum threshold. However, we expected to obtain esti-
mates consistent with 80% sensitivity and 80% positive predictive value (PPV) across
conditions.
Subjects and methods
This study was reviewed and approved by the Institutional Review Board of Partners Health-
Care (Partners Human Research Committees) and all participants voluntarily provided writ-
ten informed consent online prior to participation (protocol number 2013P001721).
Subjects
Females and males between the ages of 18 and 70 years at the time of enrollment were included
in the study. Patients whose primary care physician practiced at the Internal Medical Associ-
ates Primary Care Clinic at Massachusetts General Hospital (MGH) and who had an active
account in the patient portal (a web-based system designed for patients to review their medical
records and communicate with clinical providers) were identified through the Partners
Healthcare Research Patient Data Registry. Thirty-one physicians of the practice were con-
tacted, and 30 agreed to participate. Each physician reviewed the entire list of his or her
patients and indicated which patients should be asked to participate in the study. Physicians
excluded their patients based on personal judgment; potential reasons for exclusion were high
patient burden, terminal illness, or other hardships. No other patients were excluded. The
selected patients were contacted via an email signed by their physician describing the study
and asking them to participate, with the option of signing an informed consent and a link to
the secure online questionnaire. A total of 6220 patients of the 30 participating physicians were
identified as eligible, and 5,999 (96% of those eligible) were asked to participate. Among those
eligible 1,013 (17%) signed the informed consent and completed the questionnaire. Email invi-
tations were sent between July 15, 2014, and February 10, 2015. Median time to survey comple-
tion was four days.
Autoimmune history questionnaire
As part of the online autoimmune history questionnaire, patients were asked to report on a
series of 33 autoimmune diseases (S1 Questionnaire). For each disease, patients answered the
question “Have you or any of your relatives been told they have [name of condition]?” If
patients responded affirmatively, they were asked to indicate the relative with the disease
(including themselves), and the age range at which the relative with the disease was first told
they had the disease, using a dropdown menu. Patients could choose to report on more than
one relative for each disease. Patients also answered yes/no questions about autoimmune dis-
ease symptoms in the past three months and in their lifetime, questions about the numbers of
biological relatives in their families, a question about history of other health conditions, a ques-
tion about future participation in research, a question about family history of autism or devel-
opmental delay, a question about highest level of education, and an open-ended question
allowing inclusion of additional information.
The autoimmune diseases of interest for this study were chosen based on their reported
prevalence in the general population.[18] The chosen diseases, which had a population preva-
lence of 5 per 100,000 or higher, were Addison’s disease/ primary adrenocortical insufficiency,
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Graves’ disease, Hashimoto’s autoimmune thyroiditis, type 1 DM, celiac disease, Crohn’s dis-
ease, ulcerative colitis, alopecia areata, psoriasis, vitiligo, CREST syndrome, scleroderma, Sjo¨g-
ren’s syndrome, systemic lupus erythematosus (SLE), juvenile rheumatoid arthristis (JRA),
RA, multiple sclerosis (MS), and myasthenia gravis (MG).
Electronic medical record (EMR) review
The EMR for the 1,013 consented patients were extracted from the Research Patient Data Reg-
istry at Partners Healthcare and imported into a SQL Server 2016 database. EMR included
clinical notes, problem lists, billing information, results of laboratory tests and procedures,
and other information from the inpatient and outpatient encounters at MGH, authored by pri-
mary care physicians and other medical specialists. Clinical notes were reviewed if they were
created within the time-frame of 5 years prior to and 18 months after the questionnaire was
emailed. Detailed EMR review was conducted for each study participant if: 1) the problem list
contained a diagnosis for any of the 18 autoimmune diseases of interest; or 2) the text extracted
from the clinical notes indicated the possibility of a diagnosis for any of the 18 autoimmune
diseases of interest. The text from the clinical notes was extracted using structured query lan-
guage by matching keywords to the text in the clinical notes. These keywords included termi-
nology that might be used to document a particular autoimmune disease diagnosis, symptoms
that could precede the diagnosis of an autoimmune disease (S1 Table), and relevant laboratory/
pathology tests (e.g., thyroid stimulating hormone (TSH) for hypothyroidism). These keywords
were proposed by the study team and then edited by medical specialists, including primary care
physicians, gastroenterologists, endocrinologists, dermatologists, neurologists, ophthalmolo-
gists, and rheumatologists, for accuracy and inclusiveness. Text surrounding these keywords
(100 characters prior to the keyword and 100 characters after the keyword) was extracted
together with the date and the author of the note. Clinical research staff reviewed the extracted
text surrounding the keywords in order to exclude non-relevant information such as family his-
tory of autoimmune disease or an ongoing workup to rule out the diagnosis of an autoimmune
disease. If the relevance of the extracted text was not clear, the clinical research staff read
through the entire note or the whole record in the EMR for the patient. Although keyword
searches were performed on all clinical notes in the EMR, a positive autoimmune disease diag-
nosis was given only if it was described in a clinical note authored by a physician. In addition,
clinical research staff performed detailed EMR review for all individuals who self-reported pres-
ence of autoimmune disorders in the questionnaires. For any questionable diagnoses in the
EMR, one of the physicians in the study reviewed the EMR to confirm diagnosis.
Data analysis
Two by two tables were constructed for each of the 18 autoimmune diseases based on endorse-
ment of the diagnosis by self-report and EMR review. Sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) were calculated for each autoimmune dis-
ease with an observed prevalence� 0.5% by either self-report or EMR review. These calcula-
tions used the EMR diagnosis as the ‘gold standard’; i.e. the EMR diagnosis, but not necessarily
the self-report diagnosis, was presumed to be accurate. Using type 1 DM as an example, sensi-
tivity was calculated as the proportion of participants with type 1 DM, documented by EMR
review, who also self-reported type 1 DM. Specificity was calculated as the proportion of par-
ticipants without type 1 DM based on EMR review who did not self-report type 1 DM.[31]
The PPV was calculated as the proportion of participants who self-reported type 1 DM who
were also found to have type 1 DM by EMR review, i.e. the proportion of self-reported diagno-
ses confirmed by EMR review.[32] The NPV was calculated as the proportion of participants
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who did not self-report type 1 DM and did not have type 1 DM in the EMR review.[32] Data
analysis, including calculation of exact binomial confidence intervals (CIs), was conducted
using Stata Version 14.1 software (Stata Corp, College Station, TX). The power calculations for
the discussion and the post-hoc chi-square test for trend assessing for association between edu-
cation and diagnostic agreement were performed using the power oneproportion and mhodds
commands respectively.
Results
Physicians gave the study permission to contact 5,999 (96%) of 6,220 potential participants, of
whom 1,013 (16% of potential participants and 17% of those contacted) provided informed
consent to participate in the study and completed the questionnaire. Demographic characteris-
tics of the respondents are reported in Table 1. Respondents had a mean (standard deviation)
age of 52.6 (11.9) years, were 42.8% male, and were 92.7% white. Ninety-five percent of the
participants had at least a two-year college degree.
Table 2 reports the frequency of autoimmune diseases (based on self-report and EMR
review) and PPV (positive predictive value) by system. Table 3 reports estimates of sensitivity
and PPV with associated exact binomial 95% confidence intervals for those diseases with an
observed prevalence of at least 0.5% by self-report or EMR review. All specificity estimates for
diseases of observed prevalence greater than 0.5% were greater than or equal to 98% with
lower bound of the 95% CI greater than or equal to 97%. All estimates of NPV were greater
than or equal to 96% with lower bound of the 95% CI greater or equal to 95%. Our focus is on
estimation of sensitivity and PPV.
Endocrine system
The autoimmune diseases included from the endocrine system were Hashimoto’s thyroiditis,
Grave’s disease, type 1 DM, and Addison’s disease. The most prevalent autoimmune disease of
the endocrine system by both self-report (N = 33, 3%) and EMR review (N = 17, 2%) was
Hashimoto’s thyroiditis. Of the 33 participants who self-reported a Hashimoto’s thyroiditis
diagnosis and 17 participants who had the diagnosis according to EMR review, 13 had both a
Table 1. Demographics of 1,013 patients who provided informed consent and completed the autoimmune disease
questionnaire.
Characteristics N = 1,013
Age in years, Mean (St dev) 52.6 (11.9)
Sex, Number of Male (%) 434 (42.8%)
Education, Number (%)
Some high school 3 (0.3%)
High school 40 (3.9%)
Some college or 2 year degree 138 (13.6%)
College graduate 348 (34.4%)
Advanced graduate or professional degree 477 (47.1%)
Missing 7 (0.7%)
Race/Ethnicity
White 939 (92.7%)
Black 18 (1.8%)
Asian 30 (3.0%)
Hispanic 2 (0.2%)
Other or unknown 24 (2.4%)
https://doi.org/10.1371/journal.pone.0216526.t001
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self-report and EMR diagnosis. The 13 with both a self-reported and EMR-based diagnosis out
of 17 total participants with an EMR-based diagnosis corresponds to a sensitivity estimate of
76% (95% CI 50%:93%). In other words, we estimate that 76% of persons with a diagnosis of
Hashimoto’s thyroiditis verified by EMR self-report the diagnosis. The 13 with both an EMR-
based diagnosis and self-reported diagnosis out of 33 total participants with a self-reported
diagnosis corresponds to a PPV estimate of 39% (95% CI 23%:58%). In other words, we esti-
mate that 39% of persons who self-report a diagnosis of Hashimoto’s thyroiditis would have
their diagnosis verified by EMR review.
The EMR review of the 20 participants who self-reported the diagnosis of Hashimoto’s thy-
roiditis but did not have the diagnosis of Hashimoto’s thyroiditis in their EMR (33 total self-
reports minus 13 self-reports verified by EMR review) found that 14 of the participants had
the diagnosis of “hypothyroidism.” In other words, more that 80% of patients who self-
reported a diagnosis of Hashimoto’s thyroiditis had a diagnosis of hypothyroidism (with or
without specified autoimmune origin) documented in their EMR. Of the remaining six
Table 2. Prevalence of autoimmune disease diagnosis according to self-report and medical record review, and overlap of self-report and medical record endorse-
ment, by biological system.
Self-reported Diagnosis,
N (%1)
Medical Record Diagnosis,
N (%1)
Self-reported Diagnosis Supported by Medical Record Diagnosis,
N (PPV %1)
Endocrine System:
Hashimoto’s Thyroiditis 33 (3%) 17 (2%) 13 (39%)
Hypothyroidism2 108 (11%) 27 (82%)
Grave’s Disease 18 (2%) 15 (1%) 14 (78%)
Type 1 Diabetes Mellitus 12 (1%) 5 (0%) 5 (42%)
Addison’s Disease 1 (0%) 1 (0%) 0 (0%)
Gastrointestinal System:
Celiac Disease 10 (1%) 11 (1%) 9 (90%)
Ulcerative Colitis 11 (1%) 10 (1%) 7 (64%)
Crohn’s Disease 4 (0%) 6 (1%) 4 (100%)
Cutaneous System:
Psoriasis 23 (2%) 56 (6%) 17 (74%)
Alopecia 8 (1%) 23 (2%) 4 (50%)
Vitiligo 11 (1%) 4 (0%) 3 (27%)
Systemic Autoimmune Diseases:
Sjo¨gren’s Syndrome 7 (1%) 5 (0%) 5 (71%)
Systemic Lupus Erythematous 2 (0%) 3 (0%) 2 (100%)
CREST Syndrome 1 (0%) 1 (0%) 1 (100%)
Scleroderma 0 (0%) 0 (0%) 0 (0%)
Musculoskeletal System:
Rheumatoid Arthritis 22 (2%) 13 (1%) 7 (32%)
Juvenile Rheumatoid Arthritis 2 (0%) 0 (0%) 0 (0%)
Neurologic System:
Multiple Sclerosis 2 (0%) 2 (0%) 2 (100%)
Myasthenia Gravis 2 (0%) 2 (0%) 2 (100%)
1. Percentages with a self-reported and medical record diagnosis (columns 1 and 2) were calculated out of the total sample of 1,013 respondents. PPV (column 3) was
calculated as a percentage out of the number of respondents with a medical record diagnosis in column 2.
2. Most medical record diagnoses of hypothyroidism did not specify if the disease was autoimmune in origin (i.e., Hashimoto’s thyroiditis). Though only 13/33
respondents who self-reported Hashimoto’s thyroiditis had the diagnosis of Hashimoto’s thyroiditis documented in the medical record (corresponding to a PPV of
39%), 27/33 had the diagnosis of hypothyroidism documented in the medical record (corresponding to a PPV of 82%).
https://doi.org/10.1371/journal.pone.0216526.t002
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participants who self-reported a diagnosis of Hashimoto’s thyroiditis that was not documented
in their EMR, three had the diagnosis of “thyroid carcinoma,” one had the diagnosis of “Graves’
disease,” and two had no diagnosis indicative of thyroid abnormality documented. Further
review of the EMR did not provide an explanation for the four participants with an EMR diag-
nosis of Hashimoto’s thyroiditis who did not endorse the diagnosis on the questionnaire.
The second most prevalent autoimmune disease of the endocrine system was Grave’s dis-
ease. Out of 18 participants who self-reported a Grave’s disease diagnosis and 15 participants
with an EMR-based diagnosis 14 had both a self-report and EMR-based diagnosis. Out of the
four participants with a self-reported diagnosis but no accompanying diagnosis in the EMR,
three had a diagnosis of hypothyroidism, and one had no thyroid related diagnosis. The partic-
ipant with the EMR diagnosis of Graves’ disease not reflected by self-report had not yet been
diagnosed at the time of questionnaire distribution.
Twelve participants self-reported a diagnosis of type 1 DM, but only 5 participants had the
diagnosis according to EMR review, all of whom were among the 12 endorsing the diagnosis
by self-report. Of the seven participants with the self-reported diagnosis of type 1 DM but no
accompanying diagnosis in the EMR, six had a diagnosis of type 2 DM in the EMR, and one
had no related diagnosis.
The least prevalent autoimmune disease represented in the sample was Addison’s disease.
One participant self-reported the diagnosis, and one different participant was diagnosed by
EMR review. The participant with a self-reported diagnosis of Addison’s disease had the diag-
nosis of ‘left adrenal cortical adenoma, hyperaldosteronism (Conn’s syndrome), adrenalec-
tomy’ in the EMR. Further review of the EMR did not provide an explanation for the
participant with an EMR diagnosis of Addison’s disease who did not endorse the diagnosis on
the questionnaire.
Table 3. Estimated sensitivity and positive predictive value (95% confidence interval) for autoimmune diseases
with minimum 0.5% prevalence by self-report or medical record review.
Sensitivity (%) Positive Predictive Value (%)
Endocrine System:
Hashimoto’s Thyroiditis1 76 (50, 93) 39 (23, 58)
Grave’s Disease 93 (68, 100) 78 (52, 94)
Type 1 Diabetes Mellitus 100 (48, 100)2 42 (15, 72)
Gastrointestinal System:
Celiac Disease 82 (48, 98) 90 (55, 100)
Ulcerative Colitis 70 (35, 93) 64 (31, 89)
Crohn’s Disease 67 (22, 96) 100 (40, 100)2
Cutaneous System:
Psoriasis 30 (19, 44) 74 (52, 90)
Alopecia 17 (5, 39) 50 (16, 84)
Vitiligo 75 (19, 99) 27 (6, 61)
Systemic Autoimmune Diseases:
Sjo¨gren’s Syndrome 100 (48, 100)2 71 (29, 96)
Musculoskeletal System:
Rheumatoid Arthritis 54 (25, 81) 32 (14, 55)
1. Cases when a self-reported diagnosis of Hashimoto’s thyroiditis was reflected in a medical record diagnosis of
hypothyroidism, but not Hashimoto’s thyroiditis, were considered negative for Hashimoto’s thyroiditis by medical
record for these calculations.
2. One-sided 97.5% confidence interval.
https://doi.org/10.1371/journal.pone.0216526.t003
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Endocrine system: Hypothyroidism of unspecified etiology. The questionnaire asked
about the presence of the diagnosis of Hashimoto’s thyroiditis without asking about the pres-
ence of the diagnosis of ‘hypothyroidism’. Because a high percentage of self-report diagnoses
of Hashimoto’s thyroiditis not verified by EMR review had the diagnosis of ‘hypothyroidism’
in the EMR, and because we could not distinguish hypothyroidism of autoimmune origin
from hypothyroidism of other etiologies, we recalculated our PPV estimate assuming self-
report diagnoses of ‘Hashimoto’s thyroiditis’ accompanied by EMR diagnoses of ‘hypothyroid-
ism’ were accurate. Using the EMR diagnosis of ‘hypothyroidism’ instead of the diagnosis of
‘Hashimoto’s thyroiditis’ to calculate the PPV of the self-reported diagnosis of Hashimoto’s
thyroiditis increased the PPV estimate from 39% to 82%. We also reviewed the EMR of all
patients for a diagnosis of hypothyroidism of any type and identified 108 participants with the
diagnosis, among whom 17 (16%) had the diagnosis of Hashimoto’s thyroiditis and 91 (84%)
had the diagnosis of “hypothyroidism” of unspecified etiology. Low prevalence of the Hashi-
moto’s thyroiditis diagnosis in the sample may reflect the absence of known etiology for many
diagnoses of hypothyroidism, both for patients and medical professionals.
Gastrointestinal system
The autoimmune diseases included from the gastrointestinal system were celiac disease, ulcer-
ative colitis, and Crohn’s disease. Celiac disease and ulcerative colitis were more prevalent in
the sample than Crohn’s disease. Out of ten participants who self-reported a diagnosis of celiac
disease, and 11 participants with a diagnosis by EMR review, nine had both a self-report and
EMR-based diagnosis. The participant who self-reported celiac disease without confirmation
in the EMR was screened for the disease but had no diagnosis of celiac disease in the EMR.
Further review of the EMR did not provide an explanation for the two participants with an
EMR diagnosis of celiac disease who did not endorse the diagnosis on the questionnaire.
Out of 11 participants who self-reported a diagnosis of ulcerative colitis and 10 participants
who had the diagnosis by EMR review, seven had both a self-report and EMR-based diagnosis.
Out of the four participants who self-reported ulcerative colitis without an accompanying
diagnosis in the EMR, two had a diagnosis of Crohn’s disease in the EMR, and two had under-
gone diagnostic colonoscopy, which had not resulted in a formal diagnosis at the time of the
EMR review. Further review of the EMR did not provide an explanation for the three partici-
pants with an EMR diagnosis of ulcerative colitis who did not endorse the diagnosis on the
questionnaire.
Four participants self-reported a diagnosis of Crohn’s disease, and six had the diagnosis by
EMR review. All four participants who self-reported the diagnosis had the diagnosis reflected
in their EMR. One out of the two participants with an EMR diagnosis of Crohn’s disease with-
out the same self-reported diagnosis had a long-standing diagnosis of Crohn’s disease in the
EMR without any discussion of the diagnosis or symptoms, probably indicating inactive
symptoms.
Cutaneous system
The autoimmune diseases included from the cutaneous system were psoriasis, alopecia, and
vitiligo. These diseases were characterized by low estimated agreement between positive self-
report and EMR-based diagnosis. Psoriasis was the most prevalent disease of the cutaneous
system according to both self-report and EMR review, but was substantially more prevalent
according to EMR review. Twenty-three participants self-reported a diagnosis of psoriasis,
whereas 56 had the diagnosis according to EMR review. Seventeen of these participants had
both a self-report and EMR diagnosis. All six participants with the self-report diagnosis of
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psoriasis not reflected in EMR were diagnosed with other dermatologic conditions (seborrheic
keratosis; spongiotic dermatitis; alopecia areata; Raynaud’s disease, no ulcerations or lesions;
dermatology consult, suspected psoriasis; and fungal infection). Of the 36 participants with the
EMR diagnosis of psoriasis not reflected by the self-reported diagnosis of psoriasis, 29 were
diagnosed by a dermatologist or a primary care physician, and the other seven had a history of
the diagnosis documented in the primary care progress notes in the EMR. The fact that 29 par-
ticipants diagnosed by a dermatologist or a primary care physician did not self-report the diag-
nosis might indicate that the diagnosis of psoriasis is self-reported during the acute phase of
the disease but that having a history of this diagnosis is not self-reported.
Alopecia was also more prevalent by EMR review than by self-report. Eight participants
self-reported the diagnosis, whereas 23 had the diagnosis according to EMR review. Only four
of these participants had both a self-report and EMR-based diagnosis. Out of the four partici-
pants with the self-report diagnosis of alopecia unconfirmed by EMR, two had ‘skin dryness’,
one had the diagnosis of vitiligo and one had no skin diagnoses. Out of the 19 participants
with an EMR diagnosis not reflected by self-report, three recently received the diagnosis (pos-
sibly after completion of the questionnaire).
Vitiligo was more prevalent by self-report than EMR review. Eleven participants self-
reported a diagnosis of vitiligo, whereas four participants had an EMR-based diagnosis. Three
participants had a diagnosis both by self-report and EMR review. Out of the eight participants
with the self-report diagnosis of vitiligo unconfirmed by EMR, one had the diagnosis of ‘possi-
ble vitiligo’, three had other skin conditions such as psoriasis, ‘actinic keratosis’, and skin rash,
and four had no related diagnoses. Further review of the EMR did not provide an explanation
for the participant with an EMR diagnosis of vitiligo who did not endorse the diagnosis on the
questionnaire.
Systemic autoimmune diseases
The systemic autoimmune diseases included were Sjo¨gren’s syndrome, SLE, CREST syn-
drome, and scleroderma. Sjo¨gren’s Syndrome was the only systemic autoimmune disease with
observed prevalence of at least 0.5% by either self-report or EMR review. Seven participants
self-reported the diagnosis, and five participants had the diagnosis according to EMR review.
All five of the participants with the EMR-based diagnosis endorsed the disease by self-report.
Of the two participants with the self-reported diagnosis of Sjo¨gren’s syndrome, one had the
diagnosis of ‘keratoconjunctivitis sicca’ in the EMR and the other had no related diagnoses.
Two participants self-reported a diagnosis of SLE, and three received the diagnosis by EMR
review. EMR review supported the diagnosis for both participants who self-reported it. Further
review of the EMR did not provide an explanation for the participant with an EMR diagnosis
of SLE who did not endorse the diagnosis on the questionnaire. One patient had a diagnosis of
CREST syndrome both according to self-report and EMR review. No participants had either a
self-report or EMR-based diagnosis of scleroderma.
Musculoskeletal system
The autoimmune diseases included from the musculoskeletal system were RA and JRA. RA
was characterized by low estimates of agreement between self-report and EMR review.
Twenty-two participants self-reported a diagnosis of RA, and 13 had the diagnosis according
to EMR. Only seven of these participants had the diagnosis according to both self-report and
EMR. Out of the 15 participants who self-reported a diagnosis of RA not reflected in the EMR,
nine had the diagnosis of ‘osteoarthritis’, two had the diagnosis of ‘polymyalgia rheumatic’,
two had the diagnosis of ‘back pain’, and two had no related diagnoses in the EMR. Of the six
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participants with an EMR diagnosis of RA not endorsed by self-report, one was seronegative
for rheumatoid factor, and another had the diagnosis of RA as well as the diagnosis of osteoar-
thritis. Two participants self-reported a diagnosis of JRA, but no participants had a diagnosis
of JRA according to EMR review. Of the two participants with a self-reported diagnosis of
JRA, one had the diagnosis of RA and the other had no relevant diagnoses in the EMR.
Neurologic system
The autoimmune diseases included from the neurologic system were MS and MG. Both had
sample prevalence less than 0.5% by self-report and EMR review. The same two participants
had a diagnosis of MS according to both self-report and EMR review. Another two participants
had a diagnosis of MG according to both self-report and EMR review.
Discussion
The integrity of research relying on self-reported diagnosis of personal and family history of
autoimmune disease, including research associating family history of autoimmune disease
with neuropsychiatric disorders,[33–35] and in our case ASD,[36, 37] depends on the accuracy
of self-report. In this study, we compared the self-reported diagnosis of autoimmune disease
with EMR-documented diagnosis of autoimmune disease in 1,013 adult patients receiving
their medical care in a large hospital-based adult primary care practice, and found wide vari-
ability in the accuracy of self-reported diagnosis among the autoimmune diseases assessed.
This study extends the literature by demonstrating considerable inaccuracy of self-report
across different types of autoimmune diseases.
Unlike the majority of prior studies, this investigation reviewed diagnoses of autoimmune
diseases identified both through self-report and EMR keyword searches, which allowed us to
assess rates of both over-reporting and under-reporting. We first discuss the implications of
our findings on accuracy for four representative autoimmune diseases with low estimates of
sensitivity or PPV in our study: hypothyroidism, type 1 DM, RA, and psoriasis. We then dis-
cuss some key factors complicating the diagnosis of autoimmune diseases more generally.
Hashimoto’s thyroiditis
The rate of hypothyroidism of any etiology based on EMR review in our study (10.7%) was
higher than the rate for the U.S. population (4.6%)[38] possibly due to the high average age (53
years) and high proportion of individuals self-identifying with ‘white’ race (93%) in our sam-
ple. A U.S. study found mean values for TSH, which is typically elevated in patients with hypo-
thyroidism, to increase with age for each decade following the twenties and to be higher for
individuals identifying as ‘white, non-Hispanic’, than individuals of other races.[38] Hashimo-
to’s thyroiditis is the most common cause of hypothyroidism in the U.S., accounting for 90%
of cases.[39],[40] The proportion of cases of hypothyroidism in our sample (based on EMR
review) diagnosed specifically with Hashimoto’s thyroiditis was 16% (17/108), a much lower
proportion than would be expected if Hashimoto’s thyroiditis were routinely differentiated
from other types of hypothyroidism in clinical practice. Lack of differentiation of Hashimoto’s
thyroiditis from other types of thyroiditis may explain the low rate of Hashimoto’s thyroiditis
by self-report (3%) and the low PPV for the self-reported diagnosis of Hashimoto’s thyroiditis
in our study. Unfortunately, our questionnaire asked individuals to report only if they ever
received a diagnosis of Hashimoto’s thyroiditis (without defining it as an autoimmune form of
hypothyroidism), making it impossible to estimate the accuracy of self-report of hypothyroid-
ism more generally.
Accuracy of self-reported history of autoimmune disease: A pilot study
PLOS ONE | https://doi.org/10.1371/journal.pone.0216526 May 29, 2019 10 / 18
Since the treatment of hypothyroidism does not require identification of a specific etiology,
such as an autoimmune-mediated cause, it is likely that antibody tests required to differentiate
autoimmune etiologies from other causes of hypothyroidism are not typically performed in a
primary care setting. Our results indicate that neither self-report nor medical record review is
sufficient for distinguishing between hypothyroidism with or without autoimmune origin;
future studies requiring this distinction should consider validating the diagnosis with biologi-
cal markers, such as testing for thyroid peroxidase antibodies.
Type 1 DM
The present study observed over-reporting (PPV = 42%) but not under-reporting (sensitiv-
ity = 100%) of type 1 DM. Most false-positive self-reports were from participants with a diag-
nosis of type 2 DM. This type of over-reporting error is likely to occur in the presence of a
related disease with a much greater prevalence. Type 1 DM is a relatively rare autoimmune dis-
ease while type 2 DM is a more common acquired disease with varying risk factors.[41] Type 2
DM is responsible for 90%–95% of DM cases,[41] with 8.3% of the U.S. population afflicted.
[42] A tendency for a small percentage of persons with type 2 DM to misreport having type 1
DM could result in substantial inaccuracy of reports of type 1 DM.
Prior studies examining the accuracy of self-report of DM have reported PPV ranging from
64% to 98.5%,[43–50] with most studies reporting PPV above 90%. Unfortunately, these stud-
ies made no distinction in reporting accuracy between type 1 and type 2 DM. In a recent large
population study of 266,848 individuals in Australia, 23,981 (9.0%) individuals reported an
existing diagnosis of DM. In this study, the confirmation rate of self-reported DM (type 1 or
type 2) by the hospital admission records was 79%.[21] However, when researchers evaluated
the confirmation rate for type 1 DM, the PPV decreased to 42%. This suggests a much higher
false positive rate for type 1 DM than DM of either type. Reviewing medication lists, asking
about current and past insulin use, and asking about age of onset may improve the PPV of
self-report measures for type 1 DM given the more frequent need for insulin therapy and
lower age of onset for type 1 DM on average.[51] However, since the course and treatment for
these two disorders overlap, and type 2 DM has much higher prevalence,[51, 52] it is unlikely
that this would reduce the false positive rate substantially. Future studies should validate diag-
nosis of type 1 DM by laboratory testing and/or medical record review.
Rheumatoid arthritis
The PPV of 32% obtained for RA in the present study is consistent with findings from previous
studies reporting PPVs ranging from 19% to 34%.[16, 22–26] This study supported previous
suggestions[16] that over-reporting of RA was mostly due to misreporting by individuals with
other types of arthritis, such as osteoarthritis. Similar to over-reporting of type 1 DM by indi-
viduals with type 2 DM, the over-reporting of RA by individuals with osteoarthritis is due to
the greater population prevalence of osteoarthritis (4.1% for the knee and 1.9% for the hip)
than RA (0.4%).[53] In addition, accuracy of self-report of RA may depend on the questions
asked and their context. Two large population-based studies asking about diagnosis of RA as
part of extensive questionnaires about health outcomes and behaviors, the Nurse’s Health
Study and the Iowa Women’s Health Study, were able to confirm fewer than 10% of self-
reported diagnoses of RA.[25, 29] In contrast, several studies reported significant improve-
ments in the accuracy of self-report by collecting information about drug regimen,[28, 30] ask-
ing about the presence of physical symptoms (using a validated questionnaire),[30] and
inquiring whether the person is receiving medical care by a rheumatologist.[22] For example,
a population study based on a subset of the Women’s Health Initiative cohort found that PPV
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increased from 15% to 62% when women brought in their medications to be recorded by
research staff and information on the current medication was included in the analysis.[30]
Together with existing research evidence, the low PPV and sensitivity (53%) observed in the
current study suggest that future investigations should not rely on self-report diagnosis of RA
without investigating and validating their method of assessment, using, for example, medical
record review of a subset of cases.
Psoriasis
Psoriasis is a common autoimmune skin disease with prevalence estimates for the general popula-
tion ranging from 2 to 11%.[27, 54, 55] Our PPV estimate of 74% is close to the estimate of 78%
found in a large population-based study in Norway that included a clinical examination by a
dermatologist. However, our sensitivity estimate of 30% is lower than the same study’s estimate of
56%.[27] Our study found that some individuals did not self-report psoriasis even when moderate
or severe forms of the disease were present in the EMR. It is possible that this could be due to the
predominance of other serious medical concerns (such as cancer) complicating their clinical sta-
tus. In fact, self-administered questionnaires are more sensitive for serious, life-threatening, acute-
onset diseases[50] than for less serious diseases or diseases with intermittent appearance, especially
diseases of skin.[56] It is also possible that there is diagnostic confusion from the individuals’
point of view (such as confusing the term ‘psoriasis’ with ‘eczema’, which we have seen in clinical
practice) or poor communication between the health care provider and the patient due to ambig-
uous diagnostic criteria.[57] We would therefore recommend that researchers using self-report to
diagnose psoriasis should be aware that a substantial percentage of cases may go unidentified.
Potential factors explaining variability in the accuracy of self-report of autoimmune diseases
include the actual or potential impact of the diagnosis on the respondent and the complicated
course of many autoimmune diseases. Differential significance attributed to past diagnoses
can introduce bias in self-reports in family-based case control studies.[58]
Autoimmune diseases are heterogeneous disorders with varying ages of onset, which often
wax and wane throughout a person’s lifetime. The age of onset, severity, and course of illness
can be affected by pregnancy, aging, and stress. Some are more common in women than men.
Some, like type 1 DM, typically have an age of onset in childhood, whereas others have a mean
age of onset older than age 50.[18] Some, such as RA, SLE, and other autoimmune rheumatic
diseases go through a preclinical disease phase lasting from months to several years character-
ized by little or no clinical findings but with the presence of detectable autoimmune antibod-
ies.[59–64] Since the progression of autoimmune diseases can take years from the time that
diagnostic markers of autoimmunity are present in the body to the time clinical symptoms
appear and diagnosis occurs, it is possible that autoimmune diseases that will be diagnosed
eventually will not become manifest clinically at the time a family study is conducted. In addi-
tion to the variable age of onset, an exacerbation of symptoms of some autoimmune diseases
can occur during pregnancy and may go undetected in the absence of routine screening. For
instance, thyroid disease affects 15% of pregnant women, but only about 20% of women are
screened during pregnancy[65] and up to 2.5% of all pregnant women may have undiagnosed
autoimmune connective tissue diseases.[66] Furthermore, some autoimmune diseases, such as
thyroid diseases, appear during pregnancy, and then resolve after pregnancy.
Limitations of this study
There are several limitations of this study’s findings. First, as reflected by the wide confidence
intervals for our estimates, our preliminary study was not powered to demonstrate sensitivity
or PPV above our chosen threshold of 80%. For example, achieving 80% power to demonstrate
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sensitivity or PPV above 80% for an individual disease would have required 113 self-reports or
EMR reviews respectively for the disease, assuming an underlying population value of 90%.
We observed a maximum of 33 self-reports (for Hashimoto’s thyroiditis) and 56 EMR-based
diagnoses (for psoriasis). Unexpectedly, however, some of our observed sensitivity and PPV
estimates were low enough that we could conclusively demonstrate sensitivity or PPV lower
than 80%, results that demonstrate inadequate sensitivity or PPV in our setting. Although we
cannot estimate sensitivity or PPV for any of the autoimmune diseases with precision, our
results do provide evidence that the accuracy of self-reported diagnosis of autoimmune disease
should not be assumed based on face validity. Based on the small numbers of participants we
identified with autoimmune disease diagnoses, future studies may require the use of EMR or
other databases accessing health information from large populations in order to achieve sam-
ple sizes sufficient for demonstrating the accuracy of alternative diagnostic strategies. In addi-
tion, future studies using similar methods of recruitment should allow for reductions in
sample size due to physician exclusions and the requirement for allowing access to EMR.
There is limited research available on how physician involvement in patient selection for
EMR-based research studies affects patient recruitment. In our study, 4% of patients initially
identified as eligible were excluded by their primary care physicians. Our completion rate of
17% is lower than the 30% response rate previously reported for questionnaires distributed
through the patient portal,[67] a difference we attribute to asking permission for EMR access.
A second limitation is that the patients who completed the study questionnaire may not be
representative of the general population due to differences between the population eligible for
the study and the general population, response bias, or both. PPV and NPV depend on the
prevalence of disease in the population, so our estimates would not directly generalize to popu-
lations with different rates of autoimmune disease. The study sample was substantially more
educated and less racially diverse than the general population. Based on previous studies show-
ing that advanced education significantly increases the accuracy of self-report of medical dis-
eases,[50] we would expect based on educational attainment that our study population would
self-report more accurately than the general population. A post hoc test for trend found no sig-
nificant association between education level and any diagnostic disagreement between self-
report and EMR review (odds ratio estimate per category increase in education level = 0.84,
95% CI 0.68: 1.04), though we note the low representation of persons without at least some col-
lege education in our sample. Our results may also not generalize to non-white, Hispanic, and
more racially and ethnically diverse populations; and participating physicians may have
excluded many patients experiencing acute illness and other hardships from the sample.
A third limitation is that we used diagnosis based on EMR review as the ‘gold standard’ with
which to assess the accuracy of self-report diagnosis. Though we selected a patient population for
whom we expected complete records and comprehensive medical histories, some patients may
have had undiagnosed autoimmune disease or may have been misdiagnosed by their clinicians. We
also assumed that our keyword search strategy identified all patients with the targeted diagnoses in
their EMR. Fourth, the cross-sectional design of the study and low prevalence of autoimmune dis-
eases in our sample prevented us from investigating the stability of accuracy of self-report over time
and changes in the accuracy of self-report with age and time since diagnosis. Finally, we did not
attempt to investigate the accuracy of questionnaire-based diagnoses of first and second-degree rel-
atives, which have contributed to classification of autoimmune disease history in prior studies.
Conclusions
The results of this study demonstrate that patients are not accurate reporters of their own his-
tory of some autoimmune diseases. Future studies investigating the association between
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autoimmune disease history and neuropsychiatric disorders, should be aware of the limitations
of self-report as a method of diagnostic assessment. More broadly, physicians should be aware
of the limitations of self-report when questioning their patients about family history of autoim-
mune diseases, particularly when the presence of a positive history would inform medical deci-
sion-making. More extensive questioning or review of medical records may be required to
achieve adequate diagnostic accuracy.
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